HK1044905A1 - 用選擇性復合胺再吸收抑制劑抑制血小板活化的方法 - Google Patents

用選擇性復合胺再吸收抑制劑抑制血小板活化的方法

Info

Publication number
HK1044905A1
HK1044905A1 HK02106453.5A HK02106453A HK1044905A1 HK 1044905 A1 HK1044905 A1 HK 1044905A1 HK 02106453 A HK02106453 A HK 02106453A HK 1044905 A1 HK1044905 A1 HK 1044905A1
Authority
HK
Hong Kong
Prior art keywords
methods
serotonin reuptake
reuptake inhibitors
platelet activation
selective serotonin
Prior art date
Application number
HK02106453.5A
Other languages
English (en)
Inventor
L Serebruany Victor
A Gurbel Paul
m o'connor Christopher
Original Assignee
Heartdrug Research Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heartdrug Research Llc filed Critical Heartdrug Research Llc
Publication of HK1044905A1 publication Critical patent/HK1044905A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK02106453.5A 1999-05-17 2002-08-31 用選擇性復合胺再吸收抑制劑抑制血小板活化的方法 HK1044905A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/312,987 US6245782B1 (en) 1999-05-17 1999-05-17 Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
PCT/US2000/013626 WO2000069429A2 (en) 1999-05-17 2000-05-17 Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors

Publications (1)

Publication Number Publication Date
HK1044905A1 true HK1044905A1 (zh) 2002-11-08

Family

ID=23213883

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106453.5A HK1044905A1 (zh) 1999-05-17 2002-08-31 用選擇性復合胺再吸收抑制劑抑制血小板活化的方法

Country Status (7)

Country Link
US (2) US6245782B1 (zh)
EP (1) EP1183073A2 (zh)
AU (1) AU766904B2 (zh)
CA (1) CA2375219A1 (zh)
HK (1) HK1044905A1 (zh)
WO (1) WO2000069429A2 (zh)
ZA (1) ZA200109994B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836559A1 (de) 1998-08-12 2000-03-23 Antigen Gmbh Gefäß zur Entnahme von Blut
US7054949B2 (en) * 2001-01-19 2006-05-30 World Streaming Network, Inc. System and method for streaming media
DE10135315A1 (de) * 2001-07-19 2003-01-30 Bayer Ag Stents
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
US7086397B2 (en) * 2002-02-16 2006-08-08 Graham Lindley Spruiell Patient usable emergency medical kit
CA2484628A1 (en) * 2002-05-07 2003-11-20 Becton, Dickinson And Company Collection assembly
WO2003103643A1 (en) * 2002-06-10 2003-12-18 Philippe Kriwin Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor
CA2498152C (en) * 2002-09-16 2012-01-10 Sepracor Inc. Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
CA2498175A1 (en) * 2002-09-16 2004-03-25 Sepracor Inc. Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050080084A1 (en) * 2003-07-11 2005-04-14 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
EP1715856B1 (en) * 2003-12-31 2012-07-11 Actavis Group PTC ehf. Atomoxetine formulations
CN1980574A (zh) * 2004-05-06 2007-06-13 锡德克斯公司 包含舍曲林和磺基烷基醚环糊精的掩味的制剂
EP1746985A4 (en) * 2004-05-21 2010-08-11 Univ Duke METHOD FOR INCREASING THE EFFECT OF SEROTONINE RECOVERY INHIBITORS
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
AU2006264317B2 (en) 2005-07-06 2012-02-23 Sunovion Pharmaceuticals Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
ES2643602T3 (es) * 2006-03-31 2017-11-23 Sunovion Pharmaceuticals Inc. Aminas y quirales
AU2007254751A1 (en) * 2006-05-31 2007-12-13 Sepracor Inc. Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
EP2008653A1 (de) * 2007-06-28 2008-12-31 Charité-Universitätsmedizin Berlin Serotonerge Verbindungen zur Behandlung neuronaler Krankheiten
WO2009088063A1 (ja) * 2008-01-11 2009-07-16 Eisai R & D Management Co., Ltd. 医薬組成物、医薬組成物製造のための２－イミノピロリジン誘導体の使用および心疾患の治療用または改善用キット
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20100056519A1 (en) * 2008-07-15 2010-03-04 Serebruany Victor L Composition and method for reducing platelet activation and for the treatment of thrombotic events
GB0818614D0 (en) * 2008-10-10 2008-11-19 Univ Dublin City Platelet Analysis
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
KR101193566B1 (ko) * 2011-08-10 2012-10-22 고려대학교 산학협력단 마이크로칩 기반 혈소판 복합기능 검사 장치
KR101939401B1 (ko) * 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
US9414752B2 (en) 2012-11-09 2016-08-16 Elwha Llc Embolism deflector
WO2015113001A1 (en) * 2014-01-24 2015-07-30 The Arizona Board Of Regents On Behalf Of The University Of Arizona Materials, methods and devices for altering cell reactivity
PT3261645T (pt) 2015-02-27 2021-06-17 Dechra Ltd Estimulação do apetite, gestão da perda de peso, e tratamento da anorexia em cães e gatos
US20220265579A1 (en) * 2019-05-15 2022-08-25 Vasthera Co. Ltd. Composition for preventing or treating cardio-cerebrovascular disease comprising autophagy activator as active ingredient

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4444778A (en) * 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
EP0223403B1 (en) 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5130338A (en) 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5589511A (en) 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
KR930702000A (ko) 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DK0762877T3 (da) 1994-06-03 2001-07-16 Thejmde Trust Meta-substituerede arylalkylaminer og terapeutiske og diagnostiske anvendelser deraf
US5856493A (en) 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
PT768083E (pt) 1995-07-17 2003-08-29 Pfizer Sertralina para o tratamento de doentes pos-enfarte miocardico
US5830500A (en) 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
JP3526581B2 (ja) 1997-07-08 2004-05-17 ハー・ルンドベック・アクティーゼルスカブ シタロプラムの製造方法
GB9714841D0 (en) * 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
US5760243A (en) 1997-07-25 1998-06-02 Albemarle Corporation Preparation and use of 2-methyl-5-phenylisoxazolidine
CA2291072C (en) 1997-11-11 2002-08-20 H. Lundbeck A/S Method for the preparation of citalopram

Also Published As

Publication number Publication date
WO2000069429A2 (en) 2000-11-23
CA2375219A1 (en) 2000-11-23
WO2000069429A3 (en) 2001-10-04
US20020013343A1 (en) 2002-01-31
US6552014B2 (en) 2003-04-22
AU5025800A (en) 2000-12-05
EP1183073A2 (en) 2002-03-06
ZA200109994B (en) 2002-10-30
US6245782B1 (en) 2001-06-12
AU766904B2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
HK1044905A1 (zh) 用選擇性復合胺再吸收抑制劑抑制血小板活化的方法
PL364580A1 (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
IL147246A0 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
PT1749818E (pt) Derivados de fenil-piperidina como inibidores da reabsorção da serotonina
PL364821A1 (en) Phenylpiperazines as serotonin reuptake inhibitors
IL121076A0 (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL154343A0 (en) Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
IL172965A0 (en) The combination of a serotonin reuptake inhibitors and agomelatine
CA92465S (en) Hanger bracket
HUP0202687A3 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
AU4231699A (en) Inhibitors of serotonin reuptake
AU2586402A (en) Methods of improving central nervous system functioning
HUP0201884A3 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
PT1002794E (pt) Derivados de 4-(aril)(aroloxi)metilpiperidina e sua utilização como inibidores da reabsorção da serotonina e/ou noradrenalina
ZA986138B (en) Combinations of selective serotonin re-update inhibitors and B-blockers.
AU2001280234A1 (en) Myricetin as an inhibitor of serotonin n-acetyltransferase
ZA200110401B (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
HUP0303747A3 (en) Saratin for inhibiting platelet adhesion to collagen
ZA200110325B (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same.
SI1237553T1 (sl) Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
TW483444U (en) Improved structure of hanger for electroplating
TW444570U (en) Improved structure of hanger
TW465701U (en) Improved structure of hangers
TW376026U (en) Structure of hanging ornaments
TW456643U (en) Improved structure of hooked holder